After reporting on Wednesday that a mid-stage drug in clinical trials has received FDA breakthrough designation and releasing additional data from its trial on Thursday, shares of GlycoMimetics (NASDAQ: GLYC) have more than doubled, including a 19% rally on Friday as of 1 p.m EDT.GlycoMimetics is developing GMI-1271 for use in adults with relapsed or refractory acute myeloid leukemia (AML). Image source: Getty Images.Continue reading